4-氧代-1,4-二氢-2-吡啶甲酰胺 | 100047-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氧代-1,4-二氢-2-吡啶甲酰胺
• 英文名称: 4-Hydroxypicolinsaeureamid
• 英文别名: 4-hydroxypicolinamide；4-Oxo-1,4-dihydropyridine-2-carboxamide；4-oxo-1H-pyridine-2-carboxamide
• CAS: 100047-35-6
• 化学式: C₆H₆N₂O₂
• 分子量: 138.126
• InChiKey: LETSXPSXBBJUSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DE CANNABINOÏDES
  申请人：ARENA PHARM INC

  公开号：WO2011025541A1

  公开（公告）日：2011-03-03

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及某些化合物Ia的配方和调节大麻素CB2受体活性的药物组合物。本发明还涉及某些化合物Ia的配方和药物组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和药物组合物用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎症性疼痛，神经痛，作为治疗的不良反应而发生的疼痛以及与骨关节炎相关的疼痛；痛觉过敏；触觉过敏；炎症性痛觉过敏；神经痛觉过敏；急性疼痛感；骨质疏松症；多发性硬化症相关的痉挛；自身免疫性疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活性和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩侧索硬化和帕金森病。
• [EN] CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES<br/>[FR] DERIVES CYCLOALKYLE DE 3-HYDROXY-4-PYRIDINONES
  申请人：APOTEX INC

  公开号：WO2005049609A1

  公开（公告）日：2005-06-02

  The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula (I); wherein R1 is X with the proviso that R2 is Y; or R1 is T with the proviso that R2 is W; or R1 is X with the proviso that R 2 R 5 N when taken together form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl is either unsubstituted or substituted with one to three C1 to C6 alkyl groups. X is C3-C6 cycloalkyl; Y is selected from the group consisting of C1 to C6 cycloalkyl; C1 to C6 alkyl, and C1 to C6 alkyl monosubstituted with a C3-C6 cycloalkyl; T is C1 to C6 alkyl; W is C3-C6 cycloalkyl; R3 is selected from the group consisting of hydrogen and C1 to C6 alkyl; R4 is selected from the group consisting of hydrogen and C1 to C6 alkyl; R5 is selected from the group consisting of hydrogen and C1 to C6 alkyl; and its pharmaceutically acceptable salt thereof. Pharmaceutical compositions of such compounds are useful in the removal of excess body iron from patients with iron overload diseases.

  本发明提供了一种3-羟基-4-吡啶酮的环烷基衍生物，可用于螯合金属离子，如铁。描述了其制备和用途。特别是，本发明涉及化学和生物系统中铁的去除，包括具有式（I）的螯合剂；其中R1是X，但R2是Y；或R1是T，但R2是W；或R1是X，但R2R5N在一起形成从哌啶基，吗啉基，吡咯烷基或哌嗪基中选择的杂环环，其中哌啶基，吗啉基，吡咯烷基或哌嗪基的基团是未取代或用1至3个C1至C6烷基取代。X是C3-C6环烷基；Y选自由C1至C6环烷基；C1至C6烷基和C1至C6烷基单取代的C3-C6环烷基；T是C1至C6烷基；W是C3-C6环烷基；R3选自氢和C1至C6烷基的群；R4选自氢和C1至C6烷基的群；R5选自氢和C1至C6烷基的群；以及其药学上可接受的盐。这些化合物的制药组合物可用于从铁过载病患者中去除体内过量的铁。
• Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention
  申请人：Tam Fat Tim

  公开号：US20070082904A1

  公开（公告）日：2007-04-12

  The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula (I); wherein R 1 is X with the proviso that R 2 is y; or R 1 is T with the proviso that R 2 is W; or R 1 is X with the proviso that R 2 R 5 N when taken together form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morphoninyl, pyrrolidinyl or piperazinyl is either unsubstituted or substituted with one to three C 1 to C 6 alkyl groups. X is C 3 -C 6 cycloalkyl; Y is selected from the group consisting of C, to C 6 cycloalkyl; C 1 to C 6 alkyl, and C 1 to C 6 alkyl monosubstituted with a C 3 -C 6 cycloalkyl; T is C 1 to C 6 alkyl; W is C 3 -C 6 cycloalkyl; R 3 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 4 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; R 5 is selected from the group consisting of hydrogen and C 1 to C 6 alkyl; and its pharmaceutically acceptable salt thereof. Pharmaceutical compositions of such compounds are useful in the removal of excess body iron from patients with iron overload diseases.

  本发明提供了3-羟基-4-吡啶酮的环烷基衍生物，可用于螯合金属离子，如铁离子。描述了其制备和用途。特别是，本发明涉及化学和生物系统中铁的去除，包括具有式（I）的螯合剂，其中R1为X，但R2为y；或R1为T，但R2为W；或R1为X，但R2R5N在一起形成从哌啶基，吗啉基，吡咯烷基或哌嗪基中选择的杂环环，其中哌啶基，吗啉基，吡咯烷基或哌嗪基的基团是未取代的或用1至3个C1至C6烷基基团取代的。X为C3-C6环烷基；Y选自由C到C6环烷基；C1到C6烷基和C1到C6烷基单取代的C3-C6环烷基；T为C1到C6烷基；W为C3-C6环烷基；R3选自氢和C1到C6烷基的群；R4选自氢和C1到C6烷基的群；R5选自氢和C1到C6烷基的群；以及其药学上可接受的盐。这些化合物的制药组合物可用于治疗铁过载病患者的体内多余铁的去除。
• Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues
  申请人：Tam Fat Tim

  公开号：US20080096886A1

  公开（公告）日：2008-04-24

  The present invention relates to a novel process for the preparation of 1-alkyl or 1-cycloalkyl derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxamide of formula I. The process includes reacting an amine R 2 NH 2 with a compound of formula II in a solution of metal hydroxide in water to give a compound of formula III. Subsequent reaction of the compound of formula III with an acid chloride formation reagent in an inert solvent gives compounds of formula I. The acid chloride formation reagent is selected from oxalyl chloride and dimethylformamide, dimethylchloromethylene-ammonium chloride and thionyl chloride and dimethylformamide. If desired, a compound of formula I where R 5 is hydrogen may be formed when an intermediate substituent is used wherein R 5 is an alcohol protective group removable by catalytic hydrogenation.

  本发明涉及一种新型方法，用于制备式I的1-烷基或1-环烷基的3-羟基-4-氧代-1,4-二氢吡啶-2-羧酰胺衍生物。该方法包括将胺R2NH2与式II的化合物在水中的金属氢氧化物溶液中反应，以得到式III的化合物。随后，在惰性溶剂中使用酸氯化物形成试剂与式III的化合物反应，得到式I的化合物。酸氯化物形成试剂选自草酰氯和二甲基甲酰胺、二甲基氯甲基胺盐酸盐和亚磺酰氯和二甲基甲酰胺。如果需要，当使用中间体取代基时，可以形成式I的化合物，其中R5为氢，R5是通过催化氢化可去除的醇保护基。
• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20120214766A1

  公开（公告）日：2012-08-23

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，其调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎性疼痛，神经痛，由治疗副作用引起的疼痛和与骨关节炎相关的疼痛；过敏症；炎性过敏症；神经病性过敏症；急性疼痛感受；骨质疏松症；多发性硬化症相关痉挛；自身免疫疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活动和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。